PMID- 9434821
OWN - NLM
STAT- MEDLINE
DCOM- 19980129
LR  - 20190905
IS  - 0098-1532 (Print)
IS  - 0098-1532 (Linking)
VI  - 30
IP  - 3
DP  - 1998 Mar
TI  - Allogeneic peripheral blood stem cell transplant in children.
PG  - 147-51
AB  - Allogeneic peripheral blood stem cell (PBSC) transplant has recently been 
      introduced for the treatment of hematological malignancies. As the data were 
      limited mainly to adult patients, this study aimed to assess the feasibility and 
      safety of this procedure in pediatric patients and donors. Eleven children aged 
      2-16 years received allogeneic PBSC transplant for acute lymphoblastic leukemia 
      (n = 4), acute myeloid leukemia (n = 1), myelodysplastic syndrome (n = 1), severe 
      aplastic anemia (n = 3), and thalassemia (n = 2). Nine donors were human 
      leukocyte antigen (HLA)-identical siblings and the other two were one antigen 
      mismatched family members. Eight donors were younger than 18 years old (10 months 
      to 17 years). Donors were primed with granulocyte colony-stimulating factor 
      (G-CSF) at 10-16 micrograms/kg for 4-5 days. Aphereses were performed on 1 or 2 
      consecutive days, and the patients received a mean of 14.4 x 10(8)/kg nucleated 
      cells, 6.9 x 10(6)/kg CD34 cells, and 6.9 x 10(8)/kg T cells. All patients 
      achieved neutrophil counts of > 0.5 x 10(9)/l at a median of 16 days. Nine 
      patients achieved platelet counts of > 20 x 10(9)/l at a median of 13 days. Grade 
      II acute graft vs. host disease (GVHD) occurred in only one patient. Chronic GVHD 
      was not observed in the seven patients with follow-up of more than 3 months. 
      Eight patients remained in continuous complete remission after transplant ranged 
      from 2 to 26 months. Allogeneic PBSC transplant appears safe in pediatric 
      patients and donors, and it seems not to be associated with increase of acute 
      GVHD or chronic GVHD.
FAU - Li, C K
AU  - Li CK
AD  - Department of Paediatrics, Prince of Wales Hospital, Chinese University of Hong 
      Kong, Shatin, Hong Kong. ckli@cuhk.edu.hk
FAU - Yuen, P M
AU  - Yuen PM
FAU - Chik, K W
AU  - Chik KW
FAU - Shing, M M
AU  - Shing MM
FAU - Li, K
AU  - Li K
FAU - Tsang, K S
AU  - Tsang KS
FAU - Wong, A
AU  - Wong A
FAU - Leung, T F
AU  - Leung TF
FAU - Lai, H
AU  - Lai H
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PL  - United States
TA  - Med Pediatr Oncol
JT  - Medical and pediatric oncology
JID - 7506654
SB  - IM
MH  - Adolescent
MH  - Blood Component Removal
MH  - Child
MH  - Child, Preschool
MH  - Feasibility Studies
MH  - Female
MH  - Graft vs Host Disease
MH  - *Hematopoietic Stem Cell Transplantation/adverse effects
MH  - Humans
MH  - Male
MH  - *Tissue Donors
MH  - Transplantation, Homologous
MH  - Treatment Outcome
EDAT- 1998/01/22 18:02
MHDA- 2000/06/20 09:00
CRDT- 1998/01/22 18:02
PHST- 1998/01/22 18:02 [pubmed]
PHST- 2000/06/20 09:00 [medline]
PHST- 1998/01/22 18:02 [entrez]
AID - 10.1002/(SICI)1096-911X(199803)30:3<147::AID-MPO3>3.0.CO;2-H [pii]
AID - 10.1002/(sici)1096-911x(199803)30:3<147::aid-mpo3>3.0.co;2-h [doi]
PST - ppublish
SO  - Med Pediatr Oncol. 1998 Mar;30(3):147-51. doi: 
      10.1002/(sici)1096-911x(199803)30:3<147::aid-mpo3>3.0.co;2-h.